Ntouniadakis Eleftherios, Landström Fredrik
Department of Ear Nose and Throat, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Case Rep Dermatol. 2020 Dec 16;12(3):275-281. doi: 10.1159/000511697. eCollection 2020 Sep-Dec.
Apremilast (Otezla®) is a relatively novel orally administered non-biologic disease-modifying anti-rheumatic drug (DMARD) extensively used in the management of psoriasis and psoriasis arthritis, lately approved for treating oral ulcerations in Behçets disease. Its advantageous side effect profile together with its uncomplicated follow-up and monitoring when compared to other DMARDs facilitates even a broad off-label prescribing. Here, the first case of laryngeal pseudotumor in a patient treated with apremilast for plaque psoriasis is presented.
阿普米司特（Otezla®）是一种相对较新的口服非生物性改善病情抗风湿药（DMARD），广泛用于治疗银屑病和银屑病关节炎，最近被批准用于治疗白塞病的口腔溃疡。与其他DMARD相比，其有利的副作用特征以及随访和监测不复杂，这使得即使是广泛的超说明书用药也很方便。在此，报告了首例使用阿普米司特治疗斑块状银屑病的患者发生喉假性肿瘤的病例。
